Compare Fidelity National Information Servcs Inc (FIS) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Cassava Sciences Inc — how do they compare? Fidelity National Information Servcs Inc trades at $42.42 (market cap $22.05B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Fidelity National Information Servcs Inc is far larger — about 461.8× Cassava Sciences Inc's market cap, and Fidelity National Information Servcs Inc pays a 4.12% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FIS | FLNA | |
|---|---|---|
Market Cap | $22.05B | $47.75M |
Sector | Technology | Health |
52-Week High | $72.77 | $4.64 |
52-Week Low | $37.72 | $0.87 |
Enterprise Value | $42.56B | -$34.93M |
Dividend Yield | 4.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $42.51, down 0.61% today. The stock shows mixed signals with a bearish technical trend but strong fundamentals, including a low P/E of 6.57 and robust ROE of 22.33%. Recent Q2 2026 earnings beat expectations, driven by Banking Solutions growth, though full-year guidance was trimmed. Positive news includes global platform expansions in APAC and industry recognition for treasury software.
The outlook is cautiously optimistic. Attractive valuation and profitability metrics present an opportunity, but risks include execution challenges in Capital Markets and competitive pressures. Analyst consensus is strongly Buy with a $50.18 price target, suggesting significant upside potential from current levels if growth initiatives succeed.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
